MedTrace Logo

Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Subjects

NCT07323680 · Status: ENROLLING_BY_INVITATION · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-01-07

No results posted yet for this study

Summary

The purpose of this study is to compare the safety, pharmacokinetics, and pharmacodynamic effects of aspirin administered intravenously with aspirin administered orally.

Conditions

  • Healthy

Interventions

DRUG

325 mg Oral Aspirin

Drug: aspirin 325mg • Subjects will be administered 325 mg aspirin orally

DRUG

325 mg aspirin by rapid IV push

Drug: Rho-11 Subjects will be administered 325 mg aspirin by rapid IV push

Sponsors & Collaborators

  • Rhoshan Pharmaceuticals Inc

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-15
Primary Completion
2026-03-31
Completion
2026-03-31
FDA Drug
Yes

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07323680 on ClinicalTrials.gov